Gene Promoter-Methylation Signature as Biomarker to Predict Cisplatin-Radiotherapy Sensitivity in Locally Advanced Cervical Cancer

Gene Promoter-Methylation Signature as Biomarker to Predict Cisplatin-Radiotherapy Sensitivity in Locally Advanced Cervical Cancer

Despite efforts to promote health policies focused on screening and early detection, cervical cancer continues to be one of the leading causes of mortality in women; in 2020, estimated 30,000 deaths in Latin America were reported for this type of tumor. While the therapies used to treat cervical can...

Full description

Bibliographic Details
Main Authors: Carlos Contreras-Romero, Eloy-Andrés Pérez-Yépez, Antonio Daniel Martinez-Gutierrez, Alma Campos-Parra, Alejandro Zentella-Dehesa, Nadia Jacobo-Herrera, César López-Camarillo, Guillermo Corredor-Alonso, Jaime Martínez-Coronel, Mauricio Rodríguez-Dorantes, David Cantu de León, Carlos Pérez-Plasencia
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-03-01
Series:Frontiers in Oncology
Subjects:
gene promoter methylation
chemoradioresistance
cervical cancer
biomarkers
Cisplatin-Radiotherapy sensitivity
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.773438/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.773438/full

Similar Items